Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome.
about
Alternating current electrical stimulation enhanced chemotherapy: a novel strategy to bypass multidrug resistance in tumor cells.Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.Acute ethanol causes hepatic mitochondrial depolarization in mice: role of ethanol metabolism.CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.Targeting the leukemic stem cell: the Holy Grail of leukemia therapyResveratrol and P-glycoprotein inhibitors enhance the anti-skin cancer effects of ursolic acid.Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cellsNovel 5-oxo-hexahydroquinoline derivatives: design, synthesis, in vitro P-glycoprotein-mediated multidrug resistance reversal profile and molecular dynamics simulation study.Tunicamycin depresses P-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in L1210 cells.Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.Multidrug resistance 1 gene expression and AgNOR in childhood acute leukemias.Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter.
P2860
Q33236905-8C370F98-178A-4639-AE1B-83BB2819458EQ33257856-947BDD28-F8D2-450B-88F2-71FF133D4707Q33823577-B6BB206E-8316-4833-9FF1-13161A513870Q35110635-8B2CE3CE-45DF-4209-B2B8-DAFD0092D9BAQ35117523-71D35544-4057-43CA-926D-2400BD7CD3ACQ35880840-9C484513-CB4A-486E-90DA-6FC6156D3085Q36507980-25C60CD2-9F84-46C6-AAF3-E31129A9055BQ37272565-508EF8F3-8D38-45E9-9903-24893A36073AQ37407621-ACE9CA6F-1234-42C0-A89B-1AA40492CE1AQ37417569-10BA7557-7FB9-471A-8D5A-85598F2B1085Q37652854-F7F1D062-14C3-417A-862A-D7B28AD4B220Q39427313-A00BFDD1-9E58-4D98-8580-26AAD2A89D23Q40154931-FCAFBEE9-C79D-428E-B0E4-4BF4E9DCD91BQ42186987-119F6A99-E931-4FFF-B410-BDE8676F04E4Q46441674-2BD50984-6B00-4FDF-B9F2-8309426DF020Q51039534-1ADB0A24-D53B-4691-B4D3-19609DD7CDEE
P2860
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Modulation of drug resistance ...... ting myelodysplastic syndrome.
@ast
Modulation of drug resistance ...... ting myelodysplastic syndrome.
@en
Modulation of drug resistance ...... ting myelodysplastic syndrome.
@nl
type
label
Modulation of drug resistance ...... ting myelodysplastic syndrome.
@ast
Modulation of drug resistance ...... ting myelodysplastic syndrome.
@en
Modulation of drug resistance ...... ting myelodysplastic syndrome.
@nl
prefLabel
Modulation of drug resistance ...... ting myelodysplastic syndrome.
@ast
Modulation of drug resistance ...... ting myelodysplastic syndrome.
@en
Modulation of drug resistance ...... ting myelodysplastic syndrome.
@nl
P1476
Modulation of drug resistance ...... ting myelodysplastic syndrome.
@en
P2093
Douglas D Ross
P304
P356
10.1016/J.BEHA.2004.08.014
P577
2004-12-01T00:00:00Z